* Pulmonx Corp LUNG.OQ LUNG.O is expected to show a rise
in
quarterly revenue when it reports results on November 3.
* The Redwood City California-based company is expected to
report
a 12.5% increase in revenue to $14.916 million from $13.26
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pulmonx Corp is for
a
loss of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pulmonx
Corp is
$23, above its last closing price of $13.23.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.42 -0.41 -0.40 Beat 2.4
Mar. 31 2022 -0.38 -0.37 -0.43 Missed -15.9
Dec. 31 2021 -0.36 -0.36 -0.35 Beat 2.9
Sep. 30 2021 -0.37 -0.37 -0.28 Beat 24.8
Jun. -0.37 -0.37 -0.34 Beat 8.6
30 2021
Mar. 31 2021 -0.38 -0.38 -0.34 Beat 10.1
Dec. 31 2020 -0.28 -0.28 -0.27 Beat 2.9
Sep. 30 2020 -4.32 -4.32 -2.26 Beat 47.7
This summary was machine generated November 2 at 01:56 GMT. All
figures in US dollars unless otherwise stated